Scholarlink

Background <p>Early risk stratification in acute pulmonary embolism (PE) guides emergency management. Oncostatin M (OSM), an interleukin-6-family cytokine linked to endothelial activation and inflammation, may provide prognostic information complementary to established tools such as the simplified Pulmonary Embolism Severity Index (sPESI).</p> Methods <p>This prospective single-center cohort study enrolled 88 participants: 44 patients with CTPA-confirmed PE, 22 PE-negative patients, and 22 controls. Serum OSM was measured by ELISA at emergency department presentation. The primary outcome was in-hospital mortality. Contextual between-group comparisons were performed, and the incremental value of OSM beyond sPESI was assessed using parsimonious logistic regression and ROC analysis with DeLong testing.</p> Results <p>In-hospital mortality among patients with PE was 47.7% (21/44). OSM levels were higher in patients with PE than in PE-negative patients or controls (median, 277.3 vs. 143.8 and 145.8 pg/mL; <i>p</i> &lt; 0.001). Among PE patients, non-survivors had higher OSM levels than survivors (333.4 [267.9–382.8] vs. 253.7 [225.5–292.3] pg/mL; <i>p</i> = 0.004). After adjustment for sPESI, each 100 pg/mL increase in OSM showed a non-significant association with mortality (adjusted OR, 2.40; 95% CI, 0.95–6.07; <i>p</i> = 0.065). Adding OSM to sPESI numerically increased the AUC from 0.717 to 0.789, but this improvement was not significant (ΔAUC = 0.071; <i>p</i> = 0.161).</p> Conclusions <p>OSM levels were higher among non-survivors with acute PE; however, OSM did not provide statistically significant incremental discrimination beyond sPESI in this cohort. Larger multicenter studies are needed to clarify its prognostic utility.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association of Serum Oncostatin M with In-Hospital Mortality in Acute Pulmonary Embolism: A Prospective Cohort Study

  • 期刊论文

  • 发表日期：

    2026年7月8日

查看全文
  • Orhun Girgin,
  • Mustafa Burak Sayhan,
  • Eray Çeliktürk,
  • Satuk Buğra Han Bozatlı,
  • Suat Erdoğan,
  • Esin Seçgin Sayhan

摘要

Background

Early risk stratification in acute pulmonary embolism (PE) guides emergency management. Oncostatin M (OSM), an interleukin-6-family cytokine linked to endothelial activation and inflammation, may provide prognostic information complementary to established tools such as the simplified Pulmonary Embolism Severity Index (sPESI).

Methods

This prospective single-center cohort study enrolled 88 participants: 44 patients with CTPA-confirmed PE, 22 PE-negative patients, and 22 controls. Serum OSM was measured by ELISA at emergency department presentation. The primary outcome was in-hospital mortality. Contextual between-group comparisons were performed, and the incremental value of OSM beyond sPESI was assessed using parsimonious logistic regression and ROC analysis with DeLong testing.

Results

In-hospital mortality among patients with PE was 47.7% (21/44). OSM levels were higher in patients with PE than in PE-negative patients or controls (median, 277.3 vs. 143.8 and 145.8 pg/mL; p < 0.001). Among PE patients, non-survivors had higher OSM levels than survivors (333.4 [267.9–382.8] vs. 253.7 [225.5–292.3] pg/mL; p = 0.004). After adjustment for sPESI, each 100 pg/mL increase in OSM showed a non-significant association with mortality (adjusted OR, 2.40; 95% CI, 0.95–6.07; p = 0.065). Adding OSM to sPESI numerically increased the AUC from 0.717 to 0.789, but this improvement was not significant (ΔAUC = 0.071; p = 0.161).

Conclusions

OSM levels were higher among non-survivors with acute PE; however, OSM did not provide statistically significant incremental discrimination beyond sPESI in this cohort. Larger multicenter studies are needed to clarify its prognostic utility.